Changchun Changsheng Bio-Shenzhen Stock Exchange is delisted, processing results are sorted out

(The content is longer, don’t forget to think: The plot of this case is far less serious than the previous fake vaccine, but the handling far exceeds the previous cases of death from fake vaccines and far more than the 2016 Shandong fake vaccine case)

On November 12, Changsheng Biotechnology (Shenzhen 002680) was delisted from Shenzhen Stock Exchange and became the first company in mainland China to be delisted.

Report: [The company’s stock has been delisted by the Shenzhen Stock Exchange] (https://news.sina.com.cn/c/2019-11-27/doc-iihnzhfz1970162.shtml)

Case handling result:

State Administration for Market Regulation

• Ding Jianhua, Director of the Department of Drugs and Cosmetics Supervision of the State Food and Drug Administration (National Drug Administration), and Director of the Food and Drug Inspection Center, was removed from office;
• Dong Runsheng, deputy director of the Department of Pharmaceuticals and Cosmetics Supervision of the State Food and Drug Administration (State Drug Administration), was removed from office;
• Sun Jinglin, deputy director of the Department of Drugs and Cosmetics Supervision of the State Food and Drug Administration (National Food and Drug Administration) (from November 2014 to April 2017, served as the former deputy director of the Food and Drug Inspection Center of the State Food and Drug Administration) Dismissal
• Ye Guoqing, director of the Special Drug Supervision Division of the Pharmaceutical and Cosmetic Supervision Department of the State Food and Drug Administration (State Drug Administration), was removed from his post;
• Guo Xiuxia, an investigator from the Special Drugs Supervision Division of the Department of Pharmaceuticals and Cosmetics Supervision of the State Food and Drug Administration (State Drug Administration), was removed from his post;
• Wang Youchun, vice president of China Institute for Food and Drug Control, was removed from office;
• Instructed Li Bo, the president (director) of China Food and Drug Administration (formerly the Medical Device Standards Management Center of the State Food and Drug Administration), to conduct an in-depth inspection.

Central Management Officer

• Jin Yuhui, Vice Governor of Jilin Province (in charge of food and drug supervision in Jilin Province since April 2017)-removed from office
• Li Jinxiu, Vice Chairman of the CPPCC of Jilin Province (in charge of food and drug supervision in Jilin Province)-ordered to resign
• Changchun Mayor Liu Changlong-Take the blame and resign
• Bi Jingquan, Deputy Director and Party Secretary of the State Administration for Market Regulation (former Director General of Food and Drug Administration)-Take the blame and resign
• Jiang Zhiying, Member of the Standing Committee of the Jilin Provincial Party Committee and Secretary of the Party Committee of Yanbian Korean Autonomous Prefecture-made an in-depth inspection
• Jiao Hong, Director of the National Medical Products Administration-made a deep inspection

Provincial Management Officer

• Guo Hongzhi, Secretary of the Party Leadership Group and Director of Jilin Food and Drug Administration, is removed from office
• Bai Xugui, Secretary of the Party Group and Director of the Jilin Provincial Department of Industry and Information Technology (Deputy Mayor of Changchun City, who was in charge of drug supervision from April 2016 to February 2018) was removed from office
• Member of the Party Leadership Group and Deputy Director of Jilin Food and Drug Administration, Zeng Xiangdong removed
• Yan Haijiang, member of the Party Leadership Group and Deputy Director of Jilin Food and Drug Administration, was removed from office;
• Ordered Lu Feng, the deputy mayor of Changchun City and the director of the Municipal Public Security Bureau (temporary in charge of drug supervision in February 2018, and in charge of drug supervision since April 2018) to the Jilin Provincial Party Committee, the Provincial Government and the Changchun Municipal Party Committee and the Municipal Government Deep inspection

City Management Officer

• Tang Ruodi, Secretary of the Party Leadership Group and Director of the Changchun Food and Drug Administration, is removed from office.
• Zhang Wenge, member of the Party Leadership Group and Deputy Director of the Changchun Food and Drug Administration, was removed from office,
• Zhou Fuyun, the director of the Food and Drug Administration of Changchun City Food and Drug Administration, was removed from his post.
• Yu Baichuan, member of the party group and deputy director of the High-tech Zone Bureau of Changchun Food and Drug Administration, was removed from office;
• Zhao Xu, Secretary of the Party Working Committee and Director of the Management Committee of Changchun High-tech Zone, ordered his resignation
• Yang Wenjun, member of the Party Working Committee and Deputy Director of the Management Committee of Changchun New Area (deputy director of the Management Committee of Changchun New Area in June 2017, responsible for contacting the High-tech Branch of Changchun Food and Drug Administration) ordered to resign
• Yu Zhenbo, member of the Party Working Committee of Changchun Economic Development Zone and deputy director of the management committee (from February 2014 to June 2017, served as deputy director of the Changchun High-tech Zone Management Committee, responsible for contacting the Changchun Food and Drug Administration High-tech Branch) ordered by resignation *Chen Tie, secretary of the party group and director of the High-tech Zone Bureau of Changchun Food and Drug Administration, ordered his resignation.

On October 31, 2018, the Shandong Provincial Big Data Bureau was established. The first director was Ma Yuenan, who was “admonished” because of the Changchun longevity vaccine flowing into Shandong.

On March 13, 2019, the Shenzhen Stock Exchange issued an announcement stating that Changsheng Bio will be suspended from listing on March 15

On April 4, 2019, the National Medical Products Administration issued an announcement that the 19 drug approval numbers of Changsheng Biologics that had been revoked in accordance with the law before the “Drug Production License” were cancelled

On June 17, 2019, Changsheng Biotechnology received the Court’s “Administrative Ruling”, and Changchun Changsheng Biotechnology Co., Ltd. will be punished by relevant departments with “confiscation of 1.892 billion yuan of illegal income, and illegal production and sales of freeze-dried The human rabies vaccine was fined 7.212 billion yuan for three times the value of the goods, and the total fines and confiscated amounts to 9.104 billion yuan.” The administrative penalty was enforced.

June 18, 2019, Guangdong Provincial Center for Disease Control and Prevention, Jilin Branch of Bank of Communications Co., Ltd., Changchun Nanhu Industrial Group Co., Ltd., Changchun Hongri New Energy Co., Ltd. to Changsheng Biotechnology Co., Ltd. Unable to pay off the due debts and apparent lack of solvency to apply to Changchun Intermediate People’s Court for bankruptcy liquidation of Changsheng Biotechnology Co., Ltd.

On November 8, 2019, Changchun Changsheng was declared bankrupt by a civil ruling by the Intermediate People’s Court of Changchun City, Jilin Province, in accordance with the provisions of the Enterprise Bankruptcy Law of the People’s Republic of China

was delisted by the Shenzhen Stock Exchange on November 27, 2019, becoming the first company in Mainland China to be forced to delist due to major violations